(Q36675461)

15 August 2017

1 reference

title

BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma (English)

1 reference

15 August 2017

5

Sattva S Neelapu

1 reference

15 August 2017

Seung-Tae Lee

1

1 reference

15 August 2017

Yun-Fang Jiang

series ordinal

2

1 reference

15 August 2017

Keon-Uk Park

series ordinal

3

1 reference

15 August 2017

Alison F Woo

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

113-122

1 reference

15 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Follicular lymphoma: time for a re-think?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Antibody to a molecularly-defined antigen confined to a tumour cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Targeting the innate immune response with improved vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

The enemy within: keeping self-reactive T cells at bay in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.113

21 January 2018

Identifiers

DOI

10.1517/14712598.7.1.113

1 reference

15 August 2017

1 reference